Clinical trial
Iressa Versus Docetaxel (Taxotere)
NCT00076388 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00076388 |
|---|---|
| Title | Iressa Versus Docetaxel (Taxotere) |
| Official title | A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA®) Versus Intravenous Docetaxel (TAXOTERE®) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | Gefitinib, Docetaxel |
| Enrollment | 1,440 |
| Start date | Feb 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Jan 23, 2004 |
| Last update posted | May 13, 2011 |
| Countries | Argentina, Belgium, Brazil, Canada, China, Croatia, Denmark, Estonia, France, Germany, Hong Kong, Indonesia and 13 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: